Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President#China#Shanghai#Vaccine_Development#Clover_Biopharma#Nicholas_Jackson
Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President
Clover Biopharmaceuticals announces Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to spearhead vaccine development and collaborations.
third-news.com
October 19, 2025 at 11:04 PM
Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President#China#Shanghai#Vaccine_Development#Clover_Biopharma#Nicholas_Jackson
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions#South_Korea#Incheon#SK_bioscience#Vaccine_Development#ROTOR
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions
SK bioscience launches an AI-driven project to streamline clinical development decisions, aiming to enhance global vaccine access, especially in low-income nations.
third-news.com
July 2, 2026 at 12:04 PM
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions#South_Korea#Incheon#SK_bioscience#Vaccine_Development#ROTOR
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea#South_Korea#Incheon#SK_bioscience#Vaccine_Development#Korea_Growth_Fund
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea
SK bioscience has received board approval for a KRW 300 billion funding from the Korea Growth Fund, enhancing its ambitious vaccine development projects aimed at global health.
third-news.com
May 29, 2026 at 12:07 PM
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea#South_Korea#Incheon#SK_bioscience#Vaccine_Development#Korea_Growth_Fund
Immunostimulant Market to Exceed $288 Billion by 2034 with 9.9% CAGR Growth#None#Market_Growth#Vaccine_Development#Immunostimulant
Immunostimulant Market to Exceed $288 Billion by 2034 with 9.9% CAGR Growth
The global immunostimulant market is projected to grow from $111.97 billion in 2024 to $288.82 billion by 2034, showcasing a robust CAGR of 9.9%.
third-news.com
December 9, 2025 at 5:03 PM
Immunostimulant Market to Exceed $288 Billion by 2034 with 9.9% CAGR Growth#None#Market_Growth#Vaccine_Development#Immunostimulant
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma partners with NRC and Université de Montréal to create a groundbreaking vaccine for Pseudomonas aeruginosa infections, supported by Quebec funding.
third-news.com
October 8, 2025 at 1:47 PM
Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Dr. Stefan Kappe Appointed Director of Vaccine Development at University of Maryland#United_States#Baltimore#Vaccine_Development#Stefan_Kappe#Malaria_Research
Dr. Stefan Kappe Appointed Director of Vaccine Development at University of Maryland
Distinguished researcher Dr. Stefan Kappe has been appointed as the new director of the Center for Vaccine Development. He aims to innovate malaria vaccines and improve public health.
third-news.com
September 12, 2025 at 2:43 PM
Dr. Stefan Kappe Appointed Director of Vaccine Development at University of Maryland#United_States#Baltimore#Vaccine_Development#Stefan_Kappe#Malaria_Research
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections
Glycovax Pharma has received approval from the National Research Council of Canada to further develop a vaccine targeting deadly Pseudomonas aeruginosa infections.
third-news.com
August 18, 2025 at 1:52 PM
Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections#Canada#Montreal#Vaccine_Development#Glycovax_Pharma#Pseudomonas_aeruginosa
Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio#United_States#South_San_Francisco#Vaccine_Development#Centivax#Universal_Immunity
Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio
Centivax Inc. has successfully raised $45 million in an oversubscribed Series A funding round aimed at developing a universal flu vaccine and expanding their immunology portfolio.
third-news.com
July 8, 2025 at 8:23 PM
Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio#United_States#South_San_Francisco#Vaccine_Development#Centivax#Universal_Immunity
Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines#Canada#Montreal#Vaccine_Development#Glycovax#SLA_Adjuvant
Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines
Glycovax Pharma has announced the large-scale production of sulfated lactosyl archaeol (SLA) adjuvant, enhancing vaccine efficacy globally.
third-news.com
July 8, 2025 at 2:06 PM
Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines#Canada#Montreal#Vaccine_Development#Glycovax#SLA_Adjuvant
Abu Dhabi and Sanofi Form Strategic Alliance to Advance Vaccine Development#Abu_Dhabi#United_Arab_Emirates#Sanofi#Vaccine_Development
Abu Dhabi and Sanofi Form Strategic Alliance to Advance Vaccine Development
The Department of Health in Abu Dhabi partners with Sanofi to accelerate global vaccine development, enhancing health innovation in the region.
third-news.com
June 19, 2025 at 4:45 PM
Abu Dhabi and Sanofi Form Strategic Alliance to Advance Vaccine Development#Abu_Dhabi#United_Arab_Emirates#Sanofi#Vaccine_Development
Benchling and Merck: Partnering to Transform Vaccine Bioanalysis with Innovative Software Solutions#United_States#San_Francisco#Merck#Vaccine_Development#Benchling
Benchling and Merck: Partnering to Transform Vaccine Bioanalysis with Innovative Software Solutions
Benchling has announced a strategic collaboration with Merck to integrate a software framework that enhances bioanalytical workflows across vaccine development. This partnership aims to improve data management and compliance.
third-news.com
June 11, 2025 at 11:24 AM
Benchling and Merck: Partnering to Transform Vaccine Bioanalysis with Innovative Software Solutions#United_States#San_Francisco#Merck#Vaccine_Development#Benchling
Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives#United_States#Emeryville#Vaccine_Development#Dynavax#HEPLISAV-B
Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives
Dynavax Technologies reports impressive Q1 2025 financials with significant growth in HEPLISAV-B revenue, alongside announcements of new vaccine development initiatives.
third-news.com
May 6, 2025 at 8:25 PM
Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives#United_States#Emeryville#Vaccine_Development#Dynavax#HEPLISAV-B
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns#South_Korea#Seongnam#Avian_Influenza#SK_bioscience#Vaccine_Development
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns
SK bioscience collaborates with Korea Disease Control and Prevention Agency to create a rapid-response avian influenza vaccine to enhance global health security.
third-news.com
May 6, 2025 at 12:37 PM
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns#South_Korea#Seongnam#Avian_Influenza#SK_bioscience#Vaccine_Development
Primrose Bio Partners with Serum Institute to Create a Multi-Antigen Vaccine#India#Pune#Vaccine_Development#Primrose_Bio#Serum_Institute
Primrose Bio Partners with Serum Institute to Create a Multi-Antigen Vaccine
Primrose Bio and Serum Institute of India join forces to develop a cutting-edge multi-antigen vaccine aimed at global health challenges.
third-news.com
January 10, 2025 at 2:07 PM
Primrose Bio Partners with Serum Institute to Create a Multi-Antigen Vaccine#India#Pune#Vaccine_Development#Primrose_Bio#Serum_Institute
DIOSynVax Launches Advisory Committee to Advance Next-Gen Flu Vaccines#Cambridge#United_Kingdom#DIOSynVax#Avian_Flu#Vaccine_Development
DIOSynVax Launches Advisory Committee to Advance Next-Gen Flu Vaccines
DIOSynVax establishes a committee to enhance the development of its innovative avian influenza vaccines, focusing on safety and broader protection.
third-news.com
January 9, 2025 at 4:25 PM
DIOSynVax Launches Advisory Committee to Advance Next-Gen Flu Vaccines#Cambridge#United_Kingdom#DIOSynVax#Avian_Flu#Vaccine_Development